Letter by Wong and Demers Regarding Article, "Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial"

Circulation. 2023 Apr 4;147(14):1118. doi: 10.1161/CIRCULATIONAHA.122.062440. Epub 2023 Apr 3.

Authors

Eric K C Wong¹, Catherine Demers²

Affiliations

¹ Division of Geriatric Medicine, Department of Medicine, University of Toronto, Canada (E.K.C.W.).
² Division of Cardiology, Department of Medicine, Department of Health Research Methods, Evidence, and Impact, and Division of Cardiology, Department of Medicine, McMaster University, Canada (C.D.).

PMID: 37011074
DOI: 10.1161/CIRCULATIONAHA.122.062440

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Benzhydryl Compounds / adverse effects
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Frailty*
Heart Failure* / drug therapy
Humans
Hypoglycemic Agents
Stroke Volume

Substances

dapagliflozin
Hypoglycemic Agents
Benzhydryl Compounds